Millipore Sigma Vibrant Logo

513001 InSolution™ PD 98059 - CAS 167869-21-8 - Calbiochem

InSolution™ PD 98059, CAS 167869-21-8, is a 5 mg/ml solution in DMSO. A a cell-permeable, selective & reversible inhibitor of MAP Kinase Kinase (MEK).

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: MEK Inhibitor V

Primary Target: MAP kinase kinase (MEK)
View Products on Sigmaaldrich.com
513001
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
167869-21-8C₁₆H₁₃NO₃

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
513001-1ML
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Frasco de vidrio 1 ml
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      Catalogue Number513001
      Brand Family Calbiochem®
      SynonymsMEK Inhibitor V
      References
      ReferencesKültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
      Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
      Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
      Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
      Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.
      Product Information
      CAS number167869-21-8
      ATP CompetitiveN
      FormLiquid
      FormulationA 5 mg/ml solution of PD 98059 (Cat. No. 513000) in anhydrous DMSO.
      Hill FormulaC₁₆H₁₃NO₃
      Chemical formulaC₁₆H₁₃NO₃
      ReversibleY
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ PD 98059, CAS 167869-21-8, is a 5 mg/ml solution in DMSO. A a cell-permeable, selective & reversible inhibitor of MAP Kinase Kinase (MEK).
      Biological Information
      Primary TargetMAP kinase kinase (MEK)
      Primary Target IC<sub>50</sub>2 µM in completely blocking the 4-fold increase in MAP kinase activity produced by nerve growth factor in PC12 cells
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/37/38

      Irritating to eyes, respiratory system and skin.
      S PhraseS: 26-36

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      513001-1ML 07790788050924

      Documentation

      Licencias necesarias

      Título
      CARTA DE USO GENERAL 2016
      PRODUCTO REGULADO POR LA SAGARPA
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      InSolution™ PD 98059 - CAS 167869-21-8 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      InSolution™ PD 98059 - CAS 167869-21-8 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      513001

      Referencias bibliográficas

      Visión general referencias
      Kültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
      Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
      Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
      Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
      Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.

      Citas

      Título
    • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
    • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
    • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
    • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
    • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
    • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
    • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
    • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
    • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
    • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
    • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
      		•
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision19-August-2008 RFH
      SynonymsMEK Inhibitor V
      DescriptionSelective and cell-permeable inhibitor of MAP kinase kinase (MEK) that acts by inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP kinase substrates. Pretreatment of PC-12 cells with PD 98059 completely blocks the 4-fold increase of MAP kinase activity produced by nerve growth factor (NGF; IC50 = 2 µM); however, it has no effect on NGF-dependent tyrosine phosphorylation of the pp140trk receptor or its substrate Shc and does not block NGF-dependent activation of PI 3-kinase. Inhibits cell growth and reverses the phenotype of ras-transformed BALB 3T3 mouse fibroblasts and rat kidney cells.
      FormLiquid
      FormulationA 5 mg/ml solution of PD 98059 (Cat. No. 513000) in anhydrous DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number167869-21-8
      Chemical formulaC₁₆H₁₃NO₃
      Purity≥98% by HPLC
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze.
      Toxicity Irritant
      ReferencesKültz, D., et al. 1998. J. Biol. Chem. 273, 13645.
      Dudley, D.T., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 7686.
      Langlois, W.J., et al. 1995. J. Biol. Chem. 270, 25320.
      Pang, L., et al. 1995. J. Biol. Chem. 270, 13585.
      Waters, S.B., et al. 1995. J. Biol. Chem. 270, 20883.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.
      Citation
    • Alexandra Thiel, Mira Heinonen, Johanna Rintahaka, Tuija Hallikainen, and Annabrita Hemmes, Dan A. Dixon, Caj Haglund, and Ari Ristimaki. (2006) EXPRESSION OF CYCLOOXYGENASE-2 IS REGULATED BY GSK-3 IN GASTRIC CANCER CELLS. Journal of Biological Chemistry in press,.
    • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
    • Alexandra Thiel, et al. (2006) Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells. Journal of Biological Chemistry 281, 4564-4569.
    • Bysani Chandrasekar, et al. (2005) The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-J. Journal of Biological Chemistry 280, 26263-26277.
    • Diane Gesty-Palmer, et al. (2005) b-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. Journal of Biological Chemistry 280, 32157-32167.
    • Renee M. Marshall, et al. (2005) Cyclin T1 expression is regulated by multiple signaling pathways and mechanisms during activation of human peripheral blood lymphocytes. Journal of Immunology 175, 6402-6411.
    • Wojciech Wojciechowski, et al. (2005) Enhanced Expression of CD20 in Human Tumor B Cells is Controlled Through ERK-Dependent Mechanisms. Journal of Immunology 174, 7859-7868.
    • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    • Yona Goldshmit, et al. (2004) SOCS2 Induces Neurite Outgrowth by Regulation of Epidermal Growth Factor Receptor Activation. Journal of Biological Chemistry 279, 16349-16355.
    • Rick B. Vega, et al. (2004) Protein Kinases C and D Mediate Agonist-Dependent Cardiac Hypertrophy through Nuclear Export of Histone Deacetylase 5. Molecular and Cellular Biology 24, 8374-8385.
    • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
    • Michael J. Cross, et al. (2002) The Shb Adaptor Protein Binds to Tyrosine 766 in the FGFR-1 and Regulates the Ras/MEK/MAPK Pathway via FRS2 Phosphorylation in Endothelial Cells. Molecular Biology of the Cell 13, 2881-2893.
    • Maryse Delehedde, et al. (2002) Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochemistry Journal 366, 235-244.
      		•